Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.

MLA

Mirza, Mansoor R., et al. “Palbociclib plus Letrozole in Estrogen Receptor-Positive Advanced/Recurrent Endometrial Cancer: Double-Blind Placebo-Controlled Randomized Phase II ENGOT-EN3/PALEO Trial.” Gynecologic Oncology, vol. 192, Dec. 2024, pp. 128–36. EBSCOhost, https://doi.org/10.1016/j.ygyno.2024.12.003.

APA

Mirza, M. R., Bjørge, L., Marmé, F., Christensen, R. D., Gil-Martin, M., Auranen, A., Ataseven, B., Rubio, M. J., Salutari, V., Luczak, A. A., Runnebaum, I. B., Redondo, A., Lindemann, K., Trillsch, F., Ginesta, M. P. B., Roed, H., Kurtz, J.-E., Petersson, K. S., Nyvang, G.-B., & Sehouli, J. (2024). Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial. Gynecologic Oncology, 192, 128–136. https://doi.org/10.1016/j.ygyno.2024.12.003

Chicago

Mirza, Mansoor R, Line Bjørge, Frederik Marmé, René DePont Christensen, Marta Gil-Martin, Annika Auranen, Beyhan Ataseven, et al. 2024. “Palbociclib plus Letrozole in Estrogen Receptor-Positive Advanced/Recurrent Endometrial Cancer: Double-Blind Placebo-Controlled Randomized Phase II ENGOT-EN3/PALEO Trial.” Gynecologic Oncology 192 (December): 128–36. doi:10.1016/j.ygyno.2024.12.003.